Lupus nephritis is one of the most serious complications of systemic lupus erythematosus (SLE). It occurs when the immune system mistakenly attacks the kidneys, leading to inflammation and possibly to ...
Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard therapy alone 1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a ...
ATLANTA—A low-dose combination of mycophenolate mofetil (MMF) and tacrolimus (TAC) may be a viable option for treating refractory lupus nephritis, according to a new study by Chinese investigators.
In this video, Craig Gordon, MD, nephrologist at Tufts Medical Center and associate professor of medicine at Tufts University School of Medicine, discusses baseline characteristics in a case of lupus ...
Brad Rovin, MD, a nephrologist with the Ohio State University Wexner Medical Center, Columbus, Ohio, who worked on the phase 3 voclosprin trial, pointed to that drug's fast reduction in proteinuria in ...
The American College of Rheumatology last published recommendations for managing lupus nephritis (LN) in 2012. Since then, targeted treatments including belimumab (Benlysta) and voclosporin (Lupkynis) ...
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyva®/Gazyvaro® (obinutuzumab) in combination with mycophenolate mofetil (MMF) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback